Chemotherapy Progression Decision Score to Improve Subsequent Treatment Regimens Selection after Initial Assessment for Pancreatic Ductal Adenocarcinoma
Zhongquan Sun(Zhejiang University), Yuan Ding(Zhejiang University), Jieer Ying(Chinese Academy of Medical Sciences & Peking Union Medical College), Hao-Ning He(University of Science and Technology of China), Xin Han(West China Medical Center of Sichuan University), Linping Dong(Zhejiang University), Weilin Wang(China Pharmaceutical University), Hongfan Ding(Zhejiang University), Changlin Zou(Wenzhou Medical University), Qi Xu(China Jiliang University), Yufeng Zhong(Zhejiang University), Xiaochang Wu(Huzhou Central Hospital), Haoze Cao(Zhejiang University), Yixing Zhang(Zhejiang University), Jiali Ji(Zhejiang University)
Cited by 0
Related Papers
Hepatogastroenterology
|Hepatogastroenterology|2012|1.3k
Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial
|Journal of Clinical Oncology|2021|417
The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2023
|癌症：英文版|2023|412